Skip to main content

Table 1 Indicators of unsafe medication practice

From: Primary Care Medication Safety Surveillance with Integrated Primary and Secondary Care Electronic Health Records: A Cross-Sectional Study

  ID Potential hazard/at-risk patient group (1 April 2012) Prevalence ICC
Prescribing P1 Prescribed aspirin or clopidogrel/patients not prescribed gastro-protection who have a history of peptic ulcer 12.31 % (216/1755) 0.004
P2 Prescribed aspirin/patients prescribed warfarin without co-prescription of gastro-protection 4.52 % (77/1705) 0
P3 Prescribed an NSAID/patients prescribed warfarin 5.20 % (159/3060) 0.006
P4 Prescribed an NSAID/patients not prescribed gastro-protection who have a history of peptic ulcer 5.53 % (97/1755) 0
P5 Prescribed an NSAID/patients aged 65 or older without prescription of gastro-protection 6.20 % (1563/25,228) 0.023
P6 Prescribed an NSAID/patients with diagnosis of CKD (3b, 4, 5) or with latest eGFR <45 3.03 % (108/3570) 0.013
P7 Prescribed an NSAID/patients with diagnosis of CKD (3b, 4, 5) or with latest eGFR <45 who have been prescribed an ACEi 4.01 % (70/1746) 0.021
P8 Prescribed an NSAID/patients with diagnosis of CKD (3b, 4, 5) or with latest eGFR <45 who are prescribed an ACEi and a loop diuretic 3.99 % (27/677) 0
P9 Prescribed metformin/patients with diagnosis of CKD (4, 5) or with latest eGFR <30 3.71 % (46/1241) 0
P10 Prescribed digoxin at a daily dose of >125/patients with a diagnosis of CKD (3b, 4, 5) or with latest eGFR <45 0.31 % (11/3570) 0
P11 Prescribed an NSAID/patients with heart failure 3.17 % (94/2964) 0.003
P12 Prescribed glitazone/patients with heart failure 1.89 % (56/2964) 0.001
P13 Prescribed β-blockers/patients with unresolved asthma 4.73 % (1258/26,607) 0.002
P14 Not prescribed inhaled corticosteroid/patients with asthma prescribed a long-acting β-agonist 1.65 % (79/4796) 0.007
P15 Prescribed combined hormonal contraceptive/women with history of venous or arterial thrombosis 0.13 % (14/10,889) 0
P16 Prescribed combined hormonal contraceptive/women with a body mass index of ≥40 2.78 % (109/3927) 0.012
P17 Prescribed combined hormonal contraceptive/women aged ≥35 who are current smokers 1.12 % (171/15,286) 0.004
P18 Prescribed oral or transdermal oestrogens/women with a history of breast cancer 1.33 % (23/1724) 0.002
Monitoring M1 Missing renal function and electrolytes in the past 15 months/patients aged ≥75 on a long-term ACEi or loop diuretic 5.06 % (411/8123) 0.037
M2 Missing full blood count or liver function test in the past 3 months/patients receiving repeat methotrexate 6.74 % (31/460) 0.079
M3 Missing International Normalised Ratio test in the past 3 months/patients receiving repeat warfarin 9.95 % (244/2452) 0.213
M4 Missing thyroid function test in the past 6 months/patients receiving repeat amiodarone 38.01 % (103/271) 0.047
  1. ACEi angiotensin converting enzyme inhibitor, CKD chronic kidney disease, eGFR estimated glomerular filtration rate, ICC intra-class correlation coefficient (proportion of the total variation explained by the variation between practices), NSAID non-steroidal anti-inflammatory drug (only non-selective considered)